Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Regular exercise could reduce risk of developing physical, mental health conditions

People who take regular exercise could reduce their risk of developing around two dozen physical and mental health conditions including some cancers and dementia and slow down how quickly their body deteriorates as they age.

15 Nov 2010

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Santarus, Inc., a specialty biopharmaceutical company, today announced the commercial U.S. launch of CYCLOSET (bromocriptine mesylate) tablets. CYCLOSET is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.

15 Nov 2010

Biodel reports data on Linjeta formulation for type 1 diabetes at Technology Meeting in Bethesda

Scientists from Biodel Inc. reported new findings from the company's Linjeta, insulin glargine, "smart" basal insulin and stabilized glucagon development programs in poster presentations yesterday and today at the Tenth Annual Diabetes Technology Meeting in Bethesda, MD.

15 Nov 2010

Research roundup: Doctors' industry ties; Patient safety and residents' hours; Designing a medical home

Archives of Internal Medicine: Physician Professionalism And Changes in Physician-Industry Relationships From 2004 to 2009 -"During the last 6 years a number of efforts have aimed to reduce, and in some cases eliminate, certain types of physician-industry relationships (PIRs)," including policies "that forbid physicians from accepting samples and receiving food and beverages in offices, limiting company representatives' access to physicians' offices and clinical areas, and banning faculty participation in speaker bureaus and other forms of promotional activity," write the authors.

12 Nov 2010

ASN Annual Meeting to highlight six late-breaking clinical trials on nephrology

Six late-breaking clinical trials have been accepted for presentation next week during the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition in Denver, CO. These trials were selected based upon their potential impact to the field of nephrology.

12 Nov 2010

Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference

Reata Pharmaceuticals today announced that the company will present data on the primary endpoint from a pivotal Phase 2b clinical trial of bardoxolone methyl in patients with chronic kidney disease (CKD) and type 2 diabetes. The data will be presented in a late-breaking oral presentation at the American Society of Nephrology (ASN) Renal Week Conference to be held November 16-21, 2010, in Denver, Colorado.

12 Nov 2010

Bristol-Myers Squibb announces first large-scale diabetes initiative to develop self-management program

The Bristol-Myers Squibb Foundation today announced Together on Diabetes: Communities Uniting to Meet America's Diabetes Challenge, a 5-year, $100 million initiative to help patients living with type 2 diabetes better manage their disease beyond the doors of their doctor's office in their homes and communities and for the course of their disease.

12 Nov 2010

Women abused as kids at increased risk of developing diabetes: Study

The latest research shows that women who were victims of childhood abuse may be at increased risk of developing diabetes in adulthood. For the study the scientist team looked at 67,853 U.S. nurses in the Nurses Health Study II and found that 54 percent reported physical abuse and 34 percent reported sexual abuse before age 18. Moderate and severe physical and sexual abuse was associated with a 26 percent to 69 percent increased risk of type 2 diabetes in adulthood.

11 Nov 2010

Novel mechanism regulating circadian rhythm identified

Scientists from the Florida campus of The Scripps Research Institute have identified for the first time a novel mechanism that regulates circadian rhythm, the master clock that controls the body's natural 24-hour physiological cycle. These new findings could provide a new target not only for jet lag, shift work, and sleep disturbances, but also for disorders that result from circadian rhythm disruption, including diabetes and obesity as well as some types of cancer.

11 Nov 2010

Recommendations for safe and effective testing of artificial pancreas systems in real-life settings

Diabetes experts at a meeting convened by the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) took the next step in advancing efforts toward the development of an artificial pancreas: putting forth clinical recommendations to ensure the safe and effective testing of artificial pancreas technology in real-life situations.

11 Nov 2010

ESC emphasizes simple measures for diabetic patients to slow-down CVD progression

Diabetics can face a five times increase in the risk of developing cardiovascular disease (CVD) than non-diabetics. This leads to a seven to ten year reduction in life expectancy and a higher probability of suffering a fatal heart attack. These sad statistics have prompted the European Society of Cardiology (ESC) to mark World Diabetes Day on 14 November 2010 by emphasising the simple measures that diabetes patients should adopt to slow-down the progression of CVD and greatly improve their quality of life.

11 Nov 2010

Dietary intervention reduces emergence of diabetes-predictive autoantibodies by 50%

A Finnish study published in the November 11, 2010 issue of the New England Journal of Medicine confirms the hypothesis that infant feeding plays a role in the initiation of the disease process leading to type 1 diabetes in children carrying increased genetic disease risk.

11 Nov 2010

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced additional positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

10 Nov 2010

Nuffield Health Leeds Hospital offers incisionless TOGA Procedure for treatment of obesity

Nuffield Health Leeds Hospital announced today that it will be the first hospital in the UK to offer the incisionless TOGA® Procedure for treatment of obesity commencing in January 2011. The TOGA Procedure has been used to treat over 450 patients worldwide - its incision-free approach is very minimally invasive and offers the benefits of minimal pain and downtime, and an excellent safety profile.

10 Nov 2010

Repros third quarter net loss decreases to $1.2 million

Repros Therapeutics Inc. today announced financial results for the third quarter ended September 30, 2010 and provided an update on corporate actions.

10 Nov 2010

Diamyd completes patient screening for DiaPrevent Phase III study

Diamyd Medical has completed the screening of patients for the US Phase III study, DiaPrevent, ending the recruitment campaign. More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age have already been enrolled in the study and have received their first injection of the antigen-based therapy Diamyd® or placebo.

10 Nov 2010

Research report on current and evolving technologies in drug delivery

The drug delivery market is a rapidly evolving force in the pharmaceutical industry. Within this segment injectables have a significant role to play at present with the increasing use of proteins and peptides.

9 Nov 2010

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Arena Pharmaceuticals, Inc. and Eisai Inc. reported today that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes. In this trial, lorcaserin met all three co-primary efficacy endpoints. In addition, as described below, lorcaserin patients taking lorcaserin 10 mg twice daily (BID) achieved statistically significant improvements in multiple secondary endpoints, including HbA1c, as compared to patients randomized to placebo.

9 Nov 2010

Arena third quarter net loss increases to $36.3 million

Arena Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010. Arena also reported earlier today top-line results from its lorcaserin Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) trial.

9 Nov 2010

Childhood abuse increases risk of type 2 diabetes in women: Study

A new study of nearly 70,000 women found a clear association between abuse in childhood and adolescence and the risk of type 2 diabetes in adult women.

9 Nov 2010

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Regular exercise could reduce risk of developing physical, mental health conditions

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Biodel reports data on Linjeta formulation for type 1 diabetes at Technology Meeting in Bethesda

Research roundup: Doctors' industry ties; Patient safety and residents' hours; Designing a medical home

ASN Annual Meeting to highlight six late-breaking clinical trials on nephrology

Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference

Bristol-Myers Squibb announces first large-scale diabetes initiative to develop self-management program

Women abused as kids at increased risk of developing diabetes: Study

Novel mechanism regulating circadian rhythm identified

Recommendations for safe and effective testing of artificial pancreas systems in real-life settings

ESC emphasizes simple measures for diabetic patients to slow-down CVD progression

Dietary intervention reduces emergence of diabetes-predictive autoantibodies by 50%

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

Nuffield Health Leeds Hospital offers incisionless TOGA Procedure for treatment of obesity

Repros third quarter net loss decreases to $1.2 million

Diamyd completes patient screening for DiaPrevent Phase III study

Research report on current and evolving technologies in drug delivery

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Arena third quarter net loss increases to $36.3 million

Childhood abuse increases risk of type 2 diabetes in women: Study

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in